Merck & Co makes the accelerated approval pathway its own
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
New US nod widens the net for Entresto
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
2020 drug approvals rise despite Covid-19
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
